GLDC Antibody recognizes endogenous levels of total GLDC protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val668 of human GLDC protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Glycine decarboxylase (GLDC) is a component of a mitochondrial protein complex that catalyzes the degradation of glycine (1). The glycine cleavage system is composed of three distinct enzymes (P-, T- and L-proteins) and an additional component (H-protein) that transfers a glycine methylamine group from one enzyme to another. The GLDC protein (P-protein) is the decarboxylase that binds the methylamine group for transfer to the T-protein (2). Tumor-initiating cells in the primary non-small cell lung cancer (NSCLC) express high levels of GLDC and LIN28B, both of which are essential for the proliferation of tumor-initiating cells (3). GLDC is an oncogene that promotes tumorigenesis through its metabolic activity (3). Mutations in the corresponding GLDC gene account for the majority of reported cases of glycine encephalopathy, which is a metabolic disorder characterized by the accumulation of glycine, lethargy, hypotonia, intractable seizures, and death (4).